Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent

References

• RoseltPMeikleSKassiouMThe role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animalsEur J Drug Metab Pharmacokinet20042911615151164
   PubMed Web of Science ®Google Scholar
• HerschmanHRMolecular imaging: looking at problems, seeing solutionsScience2003302564560560814576425
   PubMed Web of Science ®Google Scholar
• RosenJEYoffeSMeerasaAVermaMGuFXNanotechnology and diagnostic imaging: new advances in contrast agent technologyJ Nanomed Nanotechnol201125115126
   Google Scholar
• WeisslederRHahnPFStarkDDSuperparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imagingRadiology19881693994033174987
   PubMed Web of Science ®Google Scholar
• ZhuDWhiteRDHardyPAWeerapreeyakulNSutthanutKJayMBiocompatible nanotemplate-engineered nanoparticles containing gadolinium: stability and relaxivity of a potential MRI contrast agentJ Nanosci Nanotech2006649961003
   Web of Science ®Google Scholar
• CaravanPEllisonJJMcMurryTJLaufferRBGadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applicationsChem Rev19999992293235211749483
   PubMed Web of Science ®Google Scholar
• BoudreauRJBurbidgeSSirrSLokenMKComparison of the biodistribution of manganese-54 DTPA and gadolinium-153 DTPA in dogsJ Nucl Med19872833493533819851
   PubMed Web of Science ®Google Scholar
• MüllerKSkepperJNPosfaiMEffect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitroBiomaterials20072891629164217178155
   PubMed Web of Science ®Google Scholar
• VoglTJHammerstinglRSchwarzWMagnetic resonance imaging of focal liver lesions: comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patientInvest Radiol199631116967088915751
   PubMed Web of Science ®Google Scholar
• BulteJWHoekstraYKammanRLSpecific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetite particlesMagn Reso Med1992251148157
   PubMed Web of Science ®Google Scholar
• KnauthMEgelhofTRothSUR WirtzCSartorKMonocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imagingANJR Am J Neuroradiol20012299102
   PubMed Web of Science ®Google Scholar
• VoglTJHammerstinglRSchwarzWSuperparamagnetic iron oxide – enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesionsRadiology199619838818878628887
   PubMed Web of Science ®Google Scholar
• ClémentOSiauveNCuenodCAFrijaGLiver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspectsTop Magn Reson Imaging1998931671829621405
   PubMedGoogle Scholar
• McLachlanSJMorrisMRLucasMAPhase I clinical evaluation of a new iron oxide MR contrast agentJ Magn Reson Imaging1994433013078061425
   PubMed Web of Science ®Google Scholar
• LiWTuttonSVuATFirst-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agentJ Magn Reson Imaging2005211465215611942
   PubMed Web of Science ®Google Scholar
• ReimerPMarxCRummenyEJSPIO-enhanced 2D-TOF MR angiography of the portal venous system: Results of an intraindividual comparisonJ Magn Reson Imaging1997769459499400835
   PubMed Web of Science ®Google Scholar
• Daldrup-LinkHEKaiserAHelbichTMacromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesionsAcad Radiol200310111237124614626298
   PubMed Web of Science ®Google Scholar
• TaupitzMWagnerSSchnorrJPhase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imagingInvest Radiol200439739440515194910
   PubMed Web of Science ®Google Scholar
• PassiraniCBarrattGDevissaguetJ-PLabarreDLong-circulating nanopartides bearing heparin or dextran covalently bound to poly(methyl methacrylate)Pharm Res1998157104610509688058
   PubMed Web of Science ®Google Scholar
• GiammonaGCarlisiBPalazzoSReaction of α,β-poly(N-hydroxyethyl)-DL-aspartamide with derivatives of carboxylic acidsJ Poly Sci Pol Chem1987251028132818
   Web of Science ®Google Scholar
• GiammonaGCavallaroGFontanaGDe GuidiGGiuffridaSMacromolecular prodrug of diflunisal. II. Investigations of in vitro release and of photochemical behaviourEur J Pharm Sci199645273282
   Web of Science ®Google Scholar
• GiammonaGPuglisiGCavallaroGSpadaroAPitarresiGChemical stability and bioavailability of acyclovir coupled to α,β-poly(N-2-hydroxyethyl)-dl-aspartamideJ Control Release1995332261271
   Web of Science ®Google Scholar
• HayashiTIwatsukiMBiodegradation of copoly(L-aspartic acid/L-glutamic acid) in vitroBiopolymers19902935495571691931
   PubMed Web of Science ®Google Scholar
• JainGLRayARSyntheses and characterization of random copolymers of aspartic acid with lactic acid and glycolic acidDie Makromolekulare Chemie19811821025572561
   Web of Science ®Google Scholar
• JeongSYKimHKwakB-KBiocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast AgentsNanoscale Research Letters20105121970197621170410
   PubMed Web of Science ®Google Scholar
• YoonS-WChungDJKimJ-HPreparation and swelling behavior of biodegradable hydrogels based on α,β-poly(N-2-hydroxyethyl-DL-aspartamide)J Appl Polym Sci2003901337413746
   Web of Science ®Google Scholar
• GiammonaGCarlisiBPitarresiGCavallaroGLiveriVTWater-soluble copolymers of an antiviral agent: synthesis and their interaction with a biomembrane modelJ Control Release1992223197204
   Web of Science ®Google Scholar
• ChoSHShinBCYukSHinventorsMultifunctional contrast agent using biocompatible polymer and preparation method Korean patent KR 10-2009-0020676; Publication number WO/2010/1042539162010
   Google Scholar
• StarkDDWeisslederRElizondoGSuperparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liverRadiology19881682973013393649
   PubMed Web of Science ®Google Scholar
• WeisslederRStarkDDEngelstadBLSuperparamagnetic iron oxide: pharmacokinetics and toxicityAJR Am J Roentgenol198915211671732783272
   PubMed Web of Science ®Google Scholar
• HammBStaksTTaupitzMContrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxideJ Magn Reson Imaging1994456596687981510
   PubMed Web of Science ®Google Scholar
• McLachlanSMorrisMLucasMPhase I clinical evaluation of a new iron oxide MR contrast agentJ Magn Reson Imaging1994433013078061425
   PubMed Web of Science ®Google Scholar
• ReimerPBalzerTFerucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applicationsEuropean Radiology20031361266127612764641
   PubMed Web of Science ®Google Scholar
• WangJChenYChenBPharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in miceInt J Nanomedicine2010586186621042548
   PubMed Web of Science ®Google Scholar
• PouliquenDLe JeuneJJPerdrisotRErmiasAJalletPIron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolismMagn Reson Imaging1991932752831881245
   PubMed Web of Science ®Google Scholar
• MaHLXuYFQiXRMaitaniYNagaiTSuperparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancersInt J Pharm20083541–221722618191350
   PubMed Web of Science ®Google Scholar
• IversenNKFrischeSThomsenKSuperparamagnetic iron oxide polyacrylic acid coated γ-Fe2O3 nanoparticles does not affect kidney function but causes acute effect on the cardiovascular function in healthy miceToxicol Appl Pharmacol2013266227628823142473
   PubMed Web of Science ®Google Scholar
• CalicetiPQuartaSMVeroneseFMCavallaroGPedoneEGiammonaGSynthesis and biopharmaceutical characterisation of new poly(hydroxyethylaspartamide) copolymers as drug carriersBiochim Biophys Acta200115282–317718611687305
   PubMed Web of Science ®Google Scholar
• ArrueboMFernández-PachecoRIbarraMRSantamariaJMagnetic nanoparticles for drug deliveryNano Today2007232232
   Web of Science ®Google Scholar
• BulteJWMKraitchmanDLIron oxide MR contrast agents for molecular and cellular imagingNMR Biomed200417748449915526347
   PubMed Web of Science ®Google Scholar
• RenshawPFOwenCSMcLaughlinACFreyTGLeighJSFerromagnetic contrast agents: a new approachMagn Reson Med1986322172253713487
   PubMed Web of Science ®Google Scholar
• CrosbyWHNormal functions of the spleen relative to red blood cells: a reviewBlood195914439940813638340
   PubMed Web of Science ®Google Scholar
• LaurentSForgeDPortMMagnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applicationsChem Rev200810862064211018543879
   PubMed Web of Science ®Google Scholar
• CorotCRobertPIdéeJ-MPortMRecent advances in iron oxide nanocrystal technology for medical imagingAdv Drug Deliv Rev200658141471150417116343
   PubMed Web of Science ®Google Scholar
• WeisslederRElizondoGWittenbergJRabitoCABengeleHHJosephsonLUltrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imagingRadiology19901754894932326474
   PubMed Web of Science ®Google Scholar
• ParkSHPradeepKAbsorption, distribution, excretion, and pharmacokinetics of 14C-pyronaridine tetraphosphate in male and female Sprague-Dawley ratsJ Biomed Biotechnol2010201059070720379367
   PubMedGoogle Scholar
• SchümannKSchäferSGForthWIron absorption and biliary excretion of transferrin in ratsRes Exp Med (Berlin)198618632152193738220
   PubMedGoogle Scholar
• HahnPFBaleWFHettigRAKamenMDWhippleGHRadioactive iron and its excretion in urine, bile, and fecesJ Exp Med193970544345119870921
   PubMedGoogle Scholar